Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia

This article was originally published here

SEP-363856 was discovered by Sunovion in collaboration with PsychoGenics using the in vivo phenotypic SmartCube platform and the artificial intelligence algorithms associated with it. Its breakthrough therapy designation

The post Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply